The cost-effectiveness of scaling-up rapid point-of-care testing for early infant diagnosis of HIV in southern Zambia.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2021
2021
Historique:
received:
03
12
2020
accepted:
22
02
2021
entrez:
10
3
2021
pubmed:
11
3
2021
medline:
16
10
2021
Statut:
epublish
Résumé
Early infant diagnosis (EID) and treatment can prevent much of the HIV-related morbidity and mortality experienced by children but is challenging to implement in sub-Saharan Africa. Point-of-care (PoC) testing would decentralize testing and increase access to rapid diagnosis. The objective of this study was to determine the cost-effectiveness of PoC testing in Southern Province, Zambia. A decision tree model was developed to compare health outcomes and costs between the standard of care (SoC) and PoC testing using GeneXpert and m-PIMA platforms. The primary health outcome was antiretroviral treatment (ART) initiation within 60 days of sample collection. Additional outcomes included ART initiation by 12 months of age and death prior to ART initiation. Costs included both capital and recurrent costs. Health outcomes and costs were combined to create incremental cost effectiveness ratios (ICERs). The proportion of children initiating ART within 60 days increased from 27.8% with SoC to 79.8-82.8% with PoC testing depending on the algorithm and platform. The proportion of children initiating ART by 12 months of age increased from 50.9% with SoC to 84.0-86.5% with PoC testing. The proportion of HIV-infected children dying prior to ART initiation decreased from 18.1% with SoC to 3.8-4.6% with PoC testing. Total program costs were similar for the SoC and GeneXpert but higher for m-PIMA. ICERs for PoC testing were favorable, ranging from $23-1,609 for ART initiation within 60 days, $37-2,491 for ART initiation by 12 months of age, and $90-6,188 for deaths prior to ART initiation. Factors impacting the costs of PoC testing, including the lifespan of the testing instruments and integrated utilization of PoC platforms, had the biggest impact on the ICERs. Integrating utilization across programs decreased costs for the EID program, such that PoC testing was cost-saving in some situations. PoC testing has the potential to improve linkage to care and ART initiation for HIV-infected infants and should be considered for implementation within EID programs to achieve equity in access to HIV services and reduce HIV-related pediatric morbidity and mortality.
Identifiants
pubmed: 33690733
doi: 10.1371/journal.pone.0248217
pii: PONE-D-20-38117
pmc: PMC7943017
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0248217Subventions
Organisme : NIAID NIH HHS
ID : R01 AI116324
Pays : United States
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
N Engl J Med. 1994 Nov 3;331(18):1173-80
pubmed: 7935654
JAMA. 2000 Mar 1;283(9):1175-82
pubmed: 10703780
AIDS. 2018 Jul 17;32(11):1453-1463
pubmed: 29746301
Lancet HIV. 2019 Mar;6(3):e182-e190
pubmed: 30737187
N Engl J Med. 2010 Jun 17;362(24):2271-81
pubmed: 20554982
J Acquir Immune Defic Syndr. 2018 Apr 1;77(4):383-392
pubmed: 29239901
PLoS One. 2017 Dec 20;12(12):e0189226
pubmed: 29261707
N Engl J Med. 2010 Jun 17;362(24):2282-94
pubmed: 20554983
Lancet HIV. 2019 Jun;6(6):e373-e381
pubmed: 30987937
Clin Infect Dis. 2018 Feb 1;66(4):576-585
pubmed: 29401270
MMWR Morb Mortal Wkly Rep. 2016 Nov 25;65(46):1285-1290
pubmed: 27880749
Lancet. 2008 Jul 26;372(9635):300-13
pubmed: 18657709
Bull World Health Organ. 2012 May 1;90(5):348-56
pubmed: 22589568
N Engl J Med. 2008 Jul 10;359(2):119-29
pubmed: 18525035
Clin Infect Dis. 2018 Aug 16;67(5):701-707
pubmed: 29490026
PLoS One. 2018 Jun 18;13(6):e0198344
pubmed: 29912987
Lancet. 2004 Oct 2-8;364(9441):1236-43
pubmed: 15464184
Curr HIV Res. 2015;13(4):286-91
pubmed: 25845391
BMC Pediatr. 2010 Jun 17;10:44
pubmed: 20565786
PLoS One. 2018 Mar 2;13(3):e0193577
pubmed: 29499042
PLoS One. 2014 Jan 24;9(1):e87028
pubmed: 24475214
J Acquir Immune Defic Syndr. 2011 Aug 1;57(4):319-25
pubmed: 21423025
BMC Pediatr. 2017 Mar 08;17(1):66
pubmed: 28270134
J Acquir Immune Defic Syndr. 2009 Nov 1;52(3):406-16
pubmed: 19730269
BMC Infect Dis. 2020 Mar 18;20(1):227
pubmed: 32183751